Heat Biologics, Inc.
HTBX, a clinical stage biopharmaceutical company focused on
the development of novel cancer immunotherapies, today announced that
it has filed an investigational new drug (IND) application with the
U.S. Food and Drug Administration (FDA) for its second product
candidate, HS-410, which will be evaluated in bladder cancer.
The Company also named Melissa Price, Ph.D., as Vice President,
Clinical and Regulatory Affairs. Dr. Price will be responsible for
the implementation of Heat's HS-410 bladder cancer program, as well
as all of the Company's clinical studies. Dr. Price will also direct
the company's regulatory strategy.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in